Roche has recorded a successful full year 2017, with sales driven by MS drug Ocrevus and cancer treatments Tecentriq, Perjeta and Alecensa, helping it to boost overall sales by 5% to C
Pharma often accuses the NHS of being behind the curve when it comes to adopting the latest CAR-T therapies – but England's health service is already doing the groundwork to get the la
While CAR-T therapies could vastly improve outcomes in some types of blood cancer, finding ways to replicate this effectively and safely in solid tumours remains a challenge.
